ICLR N Stock Overview
A clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 5/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
ICON Public Limited Company Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4,286.08 |
| 52 Week High | US$5,911.37 |
| 52 Week Low | US$4,150.00 |
| Beta | 1.25 |
| 11 Month Change | -26.28% |
| 3 Month Change | n/a |
| 1 Year Change | -7.72% |
| 33 Year Change | -22.77% |
| 5 Year Change | n/a |
| Change since IPO | -17.60% |
Recent News & Updates
Recent updates
Shareholder Returns
| ICLR N | MX Life Sciences | MX Market | |
|---|---|---|---|
| 7D | 3.3% | 0% | 0% |
| 1Y | -7.7% | 0% | 0% |
Return vs Industry: ICLR N underperformed the MX Life Sciences industry which returned 1.2% over the past year.
Return vs Market: ICLR N underperformed the MX Market which returned -3.1% over the past year.
Price Volatility
| ICLR N volatility | |
|---|---|
| ICLR N Average Weekly Movement | n/a |
| Life Sciences Industry Average Movement | 0% |
| Market Average Movement | 0% |
| 10% most volatile stocks in MX Market | 0% |
| 10% least volatile stocks in MX Market | 0% |
Stable Share Price: ICLR N's share price has been volatile over the past 3 months compared to the MX market.
Volatility Over Time: Insufficient data to determine ICLR N's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | 42,250 | Steve Cutler | www.iconplc.com |
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also offers clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization.
ICON Public Limited Company Fundamentals Summary
| ICLR N fundamental statistics | |
|---|---|
| Market cap | Mex$319.22b |
| Earnings (TTM) | Mex$15.25b |
| Revenue (TTM) | Mex$169.36b |
20.9x
P/E Ratio1.9x
P/S RatioIs ICLR N overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ICLR N income statement (TTM) | |
|---|---|
| Revenue | US$8.31b |
| Cost of Revenue | US$5.85b |
| Gross Profit | US$2.46b |
| Other Expenses | US$1.71b |
| Earnings | US$747.89m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 9.06 |
| Gross Margin | 29.64% |
| Net Profit Margin | 9.00% |
| Debt/Equity Ratio | 35.1% |
How did ICLR N perform over the long term?
See historical performance and comparison